Литература

1. Aberg, A. Cessation of smoking after myocardial infarction. Effects on mortality after 10 years / A. Aberg, R. Bergstrand, S. Johansson et al. // Br. Heart J. – 1983. – Vol. 49. – P. 416–422.

2. Al-Mallah, M. H. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials / M. H. Al-Mallah, I. M. Tleyjeh, A. A. Abdel-Latif et al. // J. Am. Coll. Cardiol. – 2006. – Vol. 47. – P. 1576–1583.

3. Ambrosioni, E. The effect of the angiotensinconverting- enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators / E. Ambrosioni, C. Borghi, B. Magnani // N. Engl. J. Med. – 1995. – Vol. 332. – P. 80–85.

4. Andreotti, F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients / F. Andreotti, L. Testa, F. Crea et al. // Eur. Heart J. – 2006. – Vol. 27. – P. 519–526.

5. Angiolillo, D. J. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives / D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo et al. // J. Am. Coll. Cardiol. – 2007. – P. 1505–1516.

6. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of longterm oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infraction // Lancet. – 1994. – Vol. 343. – P. 499–503.

7. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. – 2002. – Vol. 324. – P. 71–86.

8. Antman, E. M. 2007 focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With St-Elevation Myocardial Infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With St- Elevation Myocardial Infarction) / E. M. Antman, M. Hand, P. W. Armstrong et al. // Circulation. – 2008. – Vol. 117. – P. 296–329.

9. Baker, W. L. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease / W. L. Baker, C. I. Coleman, J. Kluger et al. // Ann. Intern. Med. – 2009. – Vol. 151, № 12. – P. 861–871.

10. Bangalore, S. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction (PROVE IT-TIMI) 22 Trial / S. Bangalore, J. Qin, S. Sloan et al. // Circulation. – 2010. – Vol. 122, № 21. – P. 2142–2151.

11. Bartnik, M. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction / M. Bartnik, K. Malmberg, A. Norhammar et al. // Eur. Heart J. – 2004. – Vol. 25. – P. 1990–1997.

12. Bassand, J. P. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes / J. P. Bassand, C. W. Hamm, D. Ardissino et al. // Eur. Heart J. – 2007. – Vol. 28. – P. 1598–1660.

13. Bhatt, D. L. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents / D. L. Bhatt, J. Scheiman, N. S. Abraham et al. // J. Am. Coll. Cardiol. – 2008. – Vol. 52. – P. 1502–1517.

14. Boden, W. E. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease / W. E. Boden, R. A. O’Rourke, K. K. Teo et al. // N. Engl. J. Med. – 2007. – Vol. 356, № 15. – P. 1503–1516.

15. Boden, W. E. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT) / W. E. Boden, W. H. van Gilst, R. G. Scheldewaert et al. // Lancet. – 2000. – Vol. 355. – P. 1751–1756.

16. Camm, A. J. The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation / A. J. Camm, P. Kirchhov, G. Y. H. Lip et al. // Eur. Heart J. – 2010. – Vol. 31. – P. 2369–2429.

17. Campbell, C. L. Variability in response to aspirin: do we understand the clinical relevance? / C. L. Campbell, S. R. Steinhubl // J. Thromb. Haemost. – 2005. – Vol. 4. – P. 665–669.

18. Campo, G. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy / G. Campo, L. Fileti, N. de Cesare et al. // J. Am. Coll. Cardiol. – 2010. – Vol. 56, № 18. – P. 1447–1455.

19. Carney, R. M. Depression and five year survival following acute myocardial infarction: a prospective study / R. M. Carney, K. E. Freedland, J. A. Blumenthal et al. // J. Affect. Disord. – 2008. – Vol. 109, № 1–2. – P. 133–138.

20. Carney, R. M. History of depression and survival after acute myocardial infarction / R. M. Carney, K. E. Freedland, B. Steinmeyer et al. // Psychosom. Med. – 2009. – Vol. 71, № 3. – P. 253–259.

21. Cuisset, T. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting / T. Cuisset, C. Frere, J. Quilici et al. // J. Am. Coll. Cardiol. – 2006. – Vol. 48, № 7. – P. 1339–1345.

22. Dagenais, G. R. Angiotensin-converting enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials / G. R. Dagenais, J. Pogue, K. Fox et al. // Lancet. – 2006. – Vol. 368. – P. 581–588.

23. Dale, K. M. Impact of statin dosing intensity on transaminase and creatine kinase / K. M. Dale, C. M. White, N. N. Henyan et al. // Am. J. Med. – 2007. – Vol. 120. – P. 706–712.

24. Danchin, N. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials / N. Danchin, M. Cucherat, C. Thuillez et al. // Arch. Intern. Med. – 2006. – Vol. 66. – P. 787–796.

25. Daskalopoulou, S. S. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study / S. S. Daskalopoulou, J. A. Delaney, K. B. Filion et al. // Eur. Heart J. – 2008. – Vol. 29. – P. 2083–2091.

26. Dawood, T. Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk / T. Dawood, E. A. Lambert, D. A. Barton et al. // Hypertens. Res. – 2007. – Vol. 30, № 4. – P. 285–293.

27. De Lemos, J. A. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial / J. A. de Lemos, M. A. Blazing, S. D. Wiviott et al. // JAMA. – 2004. – Vol. 292. – P. 1307–1316.

28. Dhabhar, F. S. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression / F. S. Dhabhar, H. M. Burke, E. S. Epel et al. // J. Psychiatr. Res. – 2009. – Vol. 43, № 11. – P. 962–969.

29. Dickstein, K. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan / K. Dickstein, J. Kjekshus // Lancet. – 2002. – Vol. 360. – P. 752–760.

30. Dorn, J. M. Periodontal disease and recurrent cardiovascular events in survivors of myocardial infarction (MI): the Western New York Acute MI Study / J. M. Dorn, R. J. Genco, S. G. Grossi et al. // J. Periodontol. – 2010. – Vol. 81, № 4. – P. 502–511.

31. Erne, P. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial / P. Erne, A. W. Schoenenberger, D. Burckhardt et al. // JAMA. – 2007. – Vol. 297, № 18. – P. 1985–1991.

32. Fitchett, D. Results of the ONTARGET and TRANSCEND studies: an update and discussion / D. Fitchett // Vasc. Health. Risk. Manag. – 2009. – Vol. 5, № 1. – P. 21–29.

33. Fox, K. A. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial / K. A. Fox, S. R. Mehta, R. Peters et al. // Circulation. – 2004. – Vol. 110. – P. 1202–1208.

34. Fox, K. Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology / K. Fox, M. A. Garcia, F. Crea et al. // Eur. Heart J. – 2006. – Vol. 27, № 11. – P. 1341–1381.

35. Freemantle, N. Beta blockade after myocardial infarction: systematic review and meta regression analysis / N. Freemantle, J. Cleland, P. Young et al. // BMJ. – 1999. – Vol. 318. – P. 1730–1737.

36. Gibson, R. S. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non- Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second danish verapamil infarction trial studies / R. S. Gibson, J. F. Hansen, F. Messerli et al. // Am. J. Cardiol. – 2000. – Vol. 86, № 3. – P. 275–279.

37. Gislason, G. H. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction / G. H. Gislason, S. Jacobsen, J. N. Rasmussen et al. // Circulation. – 2006. – Vol. 113, № 25. – P. 2868–2870.

38. GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results from the GISSI Prevenzione trial. Gruppo Italiano per lo Studio della Sopravivvenza nell’Infarcto miocardico // Lancet. – 1999. – Vol. 354. – P. 447–455.

39. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico // Lancet. – 1994. – Vol. 343. – P. 1115–1122.

40. Goldstein, R. E. Adverse Experience Committee, Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction / R. E. Goldstein, S. J. Boccuzzi, D. Cruess et al. // Circulation. – 1991. – Vol. 83. – P. 52–60.

41. Graham, I. European guidelines on cardiovascular disease prevention in clinical practice: executive summary / I. Graham, D. Atar, K. Borch-Johnsen et al. // Eur. Heart J. – 2007. – Vol. 28. – P. 2375–2414.

42. Hansen, B. H. Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD) / B. H. Hansen, J. A. Hanash, A. Rasmussen et al. // Trials. – 2009. – Vol. 10. – P. 20.

43. ISIS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group // Lancet. – 1995. – Vol. 345. – P. 669–685.

44. Josan, K. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials / K. Josan, S. R. Majumdar, F. A. McAlister // CMAJ. – 2008. – Vol. 178. – P. 576–584.

45. Karjalainen, P. P. Safety and efficacy of combined antiplatelet–warfarin therapy after coronary stenting / P. P. Karjalainen, P. Porela, A. Ylitalo et al. // Eur. Heart J. – 2007. – Vol. 28. – P. 726–732.

46. Kearney, P. M. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials / P. M. Kearney, C. Baigent, C. Patrono et al. // BMJ. – 2006. – Vol. 332. – P. 1302–1308.

47. Kober, L. A clinical trial of the angiotensin-converting- enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group / L. Kober, C. Torp- Pedersen, J. E. Carlsen et al. // N. Engl. J. Med. – 1995. – Vol. 333. – P. 1670–1676.

48. Krasopoulos, G. Aspirin ≪resistance≫ and risk of cardiovascular morbidity: systematic review and meta-analysis / G. Krasopoulos, S. J. Brister, W. S. Beattie et al. // BMJ. – 2008. – Vol. 336, № 7637. – P. 195–198.

49. Libby, P. Inflammation and atherosclerosis / P. Libby, P. M. Ridker, A. Maseri // Circulation. – 2002. – Vol. 105, № 9. – P. 1135–1143.

50. Matetzky, S. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction / S. Matetzky, B. Shenkman, V. Guetta et al. // Circulation. – 2004. – Vol. 109, № 25. – P. 3171–3175.

51. McGettigan, P. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 / P. McGettigan, D. Henry // JAMA. – 2006. – Vol. 296. – P. 1633–1644.

52. McKenney, J. M. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force / J. M. McKenney, M. H. Davidson, T. A. Jacobson et al. // Am. J. Cardiol. – 2006. – Vol. 97. – P. 89C–94C.

53. Meine, T. J. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes / T. J. Meine, M. R. Patel, J. B. Washam et al. // Am. J. Cardiol. – 2005. – Vol. 95. – P. 976–978.

54. Mols, F. Type D personality and depressive symptoms are independent predictors of impaired health status following acute myocardial infarction / F. Mols, E. J. Martens, J. Denollet // Heart. – 2009. – Vol. 96, № 1. – P. 30–35.

55. Ozasa, N. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention / N. Ozasa, T. Kimura, T. Morimoto et al. // Am. J. Cardiol. – 2010. – Vol. 106, № 9. – P. 1225–1233.

56. Pfeffer, M. A. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators / M. A. Pfeffer, E. Braunwald, L. A. Moye et al. // N. Engl. J. Med. – 1992. – Vol. 327. – P. 669–677.

57. Pfeffer, M. A. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both / M. A. Pfeffer, J. J. McMurray, E. J. Velazquez et al. // N. Engl. J. Med. – 2003. – Vol. 349. – P. 1893–1906.

58. Price, M. J. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial / M. J. Price, P. B. Berger, D. J. Angiolillo et al. // Am. Heart J. – 2009. – Vol. 157, № 5. – P. 818–824.

59. Rauch, B. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified Omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction / B. Rauch, R. Schiele, S. Schneider et al. // Circulation. – 2010. – Vol. 122, № 21. – P. 2152–2159.

60. Regan, K. L. Depression treatment with selective serotonin reuptake inhibitors for the postacute coronary syndrome population: a literature review / K. L. Regan // J. Cardiovasc. Nurs. – 2008. – Vol. 23, № 6. – P. 489–496.

61. Ridker, P. M. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol < 70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial / P. M. Ridker, D. A. Morrow, E. Braunwald et al. // J. Am. Coll. Cardiol. – 2005. – Vol. 45, № 10. – P. 1644–1648.

62. Rosengren, A. Cardiovascular risk factors and clinical presentation in acute coronary syndromes / A. Rosengren, L. Wallentin, M. Simoons et al. // Heart. – 2005. – Vol. 91. – P. 1141–1147.

63. Rosengren, A. Sex, age, and clinical presentation of acute coronary syndromes / A. Rosengren, L. Wallentin, K. Gitt et al. // Eur. Heart J. – 2004. – Vol. 25. – P. 663–670.

64. Rubboli, A. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting / A. Rubboli, M. Milandri, C. Castelvetri et al. // Cardiology. – 2005. – Vol. 104. – P. 101–106.

65. Rubins, H. B. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group / H. B. Rubins, S. J. Robins, D. Collins et al. // N. Engl. J. Med. – 1999. – Vol. 341. – P. 410–418.

66. Ryden, L. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) / L. Ryden, E. Standl, M. Bartnik et al. // Eur. Heart J. – 2007. – Vol. 28. – P. 88–136.

67. Shaw, L. J. COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy / L. J. Shaw, D. S. Berman, D. J. Maron et al. // Circulation. – 2008. – Vol. 117, № 10. – P. 1283–1291.

68. Smith, P. The effect of warfarin on mortality and reinfarction after myocardial infarction / P. Smith, H. Arnesen, I. Holme // N. Engl. J. Med. – 1990. – Vol. 323. – P. 147–152.

69. Smith, S. C. Jr ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention / S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr et al. // J. Am. Coll. Cardiol. – 2006. – Vol. 47. – P. e1–e121.

70. Song, C. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment / C. Song, U. Halbreich, C. Han et al. // Pharmacopsychiatry. – 2009. – Vol. 42, № 5. – P. 182–188.

71. Sшrensen, R. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data / R. Sшrensen, M. L. Hansen, S. Z. Abildstrom et al. // Lancet. – 2009. – Vol. 374. – P. 1967–1974.

72. Taylor, R. S. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials / R. S. Taylor, A. Brown, S. Ebrahim et al. // Am. J. Med. – 2004. – Vol. 116. – P. 682–692.

73. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure // Lancet. – 1993. – Vol. 342. – P. 821–828.

74. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study // Circulation. – 2000. – Vol. 102. – P. 21–27.

75. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II) // Am. J. Cardiol. – 1990. – Vol. 66. – P. 779–785.

76. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet. – 2003. – Vol. 362. – P. 782–788.

77. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction // N. Engl. J. Med. – 1988. – Vol. 319. – P. 385–392. 78. The PEACE Investigators. Angiotensin-converting enzyme inhibitionin stable coronary artery disease // N. Engl. J. Med. – 2004. – Vol. 351. – P. 2058–2068.

79. Wijns, W. The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio- Thoracic Surgery (EACTS). Guidelines on myocar- dial revascularization / W. Wijns, Ph. Kolh, N. Danchin et al. // Eur. Heart J. – 2010. – Vol. 31. – P. 2501–2555.

80. Young, J. B. Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials / J. B. Young, M. E. Dunlap, M. A. Pfeffer et al. // Circulation. – 2004. – Vol. 110, № 17. – P. 2618–2626.

81. Yusuf, S. Clopidogrel in unstable angina to prevent recurrent events trail investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation / S. Yusuf, F. Zhao, S. R. Mehta et al. // N. Engl. J. Med. – 2001. – Vol. 345. – P. 494–502.

82. Yusuf, S. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators (see comments) / S. Yusuf, P. Sleight, J. Pogue et al. // N. Engl. J. Med. – 2000. – Vol. 342, № 3. – P. 145–153.

83. Yusuf, S. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies / S. Yusuf, P. Held, C. Furberg // Am. J. Cardiol. – 1991. – Vol. 67. – P. 1295–1297.